Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Share-based Compensation (2023 - 2025)

Historic Share-based Compensation for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $1.2 million.

  • Compass Therapeutics' Share-based Compensation fell 4367.61% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year increase of 1084.32%. This contributed to the annual value of $8.6 million for FY2024, which is 3986.93% up from last year.
  • Compass Therapeutics' Share-based Compensation amounted to $1.2 million in Q3 2025, which was down 4367.61% from $2.8 million recorded in Q2 2025.
  • Compass Therapeutics' Share-based Compensation's 5-year high stood at $2.8 million during Q2 2025, with a 5-year trough of $1.2 million in Q3 2025.
  • Its 3-year average for Share-based Compensation is $1.9 million, with a median of $2.0 million in 2024.
  • As far as peak fluctuations go, Compass Therapeutics' Share-based Compensation skyrocketed by 5809.0% in 2024, and later plummeted by 4367.61% in 2025.
  • Quarter analysis of 3 years shows Compass Therapeutics' Share-based Compensation stood at $1.6 million in 2023, then soared by 39.88% to $2.2 million in 2024, then plummeted by 44.68% to $1.2 million in 2025.
  • Its Share-based Compensation was $1.2 million in Q3 2025, compared to $2.8 million in Q2 2025 and $2.5 million in Q1 2025.